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Maximum IV tPA Dose for Obese Patients is Associated with Greater Likelihood 
of Hemorrhagic Conversion  and Worse Functional Outcome at Discharge
Roboan Guillen, Amy K. Starosciak, Ph.D., Felipe De Los Rios La Rosa, M.D.
INTRODUCTION
IV tissue plasminogen activator (tPA, alteplase) is the mainstay
of treatment for acute ischemic stroke at a weight-based dose of
0.9 mg/kg with a maximum limit of 90 mg for a person >100 kg
(220 lb) according to United States (US) guidelines. The
prevalence of adult obesity in the US has progressively
increased; hence, the percentage of patients receiving the
maximum dose is expected to rise as well. We examined
differences in patient characteristics and outcomes in acute
ischemic stroke (AIS) patients who were treated with the
weight-based dose (WBD) vs. the maximum dose (MD) of IV
tPA.
METHODS
We performed a historical cohort study using the local Get With
The Guidelines-Stroke database from October 2013 to April 2017.
Selection criteria included hospital admission, age ≥ 18 years,
received IV tPA as treatment for AIS, and had a recorded weight
(Figure 1).
Patients were dichotomized into WBD group (<90 mg), weighing
<100 kg, and MD group (90 mg), weighing ≥ 100 kg. We
analyzed categorical variables using Chi square tests and
continuous variables using independent samples t-tests.
RESULTS
• Patients in the MD group tended to be younger, male,
non-Hispanic, and more likely to take antidiabetic and
anticholesterol drugs than those in the WBD group
• There did not appear to be a trend for increasing volume of
overweight/obese patients over the years
RESULTS
CONCLUSIONS
• Overweight/obese patients who received MD IV tPA
were more likely to have sICH and a worse discharge
functional outcome vs. those in the WBD group
• No difference in 90-d outcomes, likely resulting from a 28%
lost to follow-up rate
• Next step: perform regression analysis to determine if the
dosing itself explains the differences in sICH and outcomes
• The small n in the MD group did not allow for subgroup






Mean (range) Mean (range)
Age, mean (range) 77 (24-104) 62 (19-98) <0.001
Weight (kg) 71 (32-99) 116 (100-182) <0.001
n (%) n (%)
Gender
Male 119 (41) 29 (76) <0.001
Female 171 (59) 9 (24)
Ethnicity
Hispanic 193 (67) 19 (50) 0.045
Non-Hispanic 97 (33) 19 (50)
Initial NIHSS
Low (0-4) 39 (13) 9 (24) 0.241
Moderate (5-10) 108 (37) 12 (32)
High (>10) 143 (50) 17 (44)
Disposition
Good (Home/rehab) 201 (69) 24 (63) 0.442
Poor 89 (31) 14 (37)
Discharge mRS
0-2 66 (23) 7 (18) <0.001
3-6 224 (77) 31 (82)
90 day mRS
0-2 100 (34) 9 (24) 0.627
3-6 111 (57) 14 (37)
Lost to follow-up 79 (27) 11 (29)
Complications
None Serious 279 (97) 37 (88) 0.038
Pneumonia 16 (6) 3   (7) 0.671
Serious Systemic 
Hemorrhage 2 (1) 1   (2) 0.33
Symptomatic ICH 9 (3) 4 (10) 0.045
Figure 1. The patient population selection based on 
exclusion and inclusion criteria
Figure 2. Discharge mRS of patients receiving 





Missing tPA dose, 
























































Figure 3. 90-d mRS of patients receiving weight-
based dose vs max dose tPA
